Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.

Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, Glass LC

The American journal of medicine1 May 2010Cited by 74 (Europe PMC)

PMID20399326DOI10.1016/j.amjmed.2009.11.019PepBankPUB-20399326

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced weight more than placebo with the same lifestyle program.
In plain wordsIn patients with diabetes, exenatide reduced weight more than placebo with the same lifestyle program.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight change
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Body weight · Metabolic and weight
Studied dose
5 microg twice daily, increased to 10 microg twice daily after 4 weeks · injection · 24 weeksAs given in this study (human).
Measurements
Weight change
−6.16 kg
exenatide
Weight change
−3.97 kg
placebo
Source sentences
Summary
Exenatide + lifestyle modification program showed greater change in weight (-6.16 +/- 0.54 kg vs -3.97 +/- 0.52 kg, P = .003), hemoglobin A(1c) (-1.21 +/- 0.09% vs -0.73 +/- 0.09%, P <.0001), systolic (-9.44 +/- 1.40 vs -1.97 +/- 1.40 mm Hg, P <.001) and diastolic blood pressure (-2.22 +/- 1.00 vs 0…
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
Report a problemFND-2039932603
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced HbA1c more than placebo with the same lifestyle program.
In plain wordsIn patients with diabetes, exenatide reduced HbA1c more than placebo with the same lifestyle program.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 microg twice daily, increased to 10 microg twice daily after 4 weeks · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.21%
exenatide
HbA1c change
−0.73%
placebo
Source sentences
Summary
Exenatide + lifestyle modification program showed greater change in weight (-6.16 +/- 0.54 kg vs -3.97 +/- 0.52 kg, P = .003), hemoglobin A(1c) (-1.21 +/- 0.09% vs -0.73 +/- 0.09%, P <.0001), systolic (-9.44 +/- 1.40 vs -1.97 +/- 1.40 mm Hg, P <.001) and diastolic blood pressure (-2.22 +/- 1.00 vs 0…
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
Report a problemFND-2039932604
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced systolic blood pressure more than placebo with the same lifestyle program.
In plain wordsIn patients with diabetes, exenatide reduced systolic blood pressure more than placebo with the same lifestyle program.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure change
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Blood pressure · Cardiovascular
Studied dose
5 microg twice daily, increased to 10 microg twice daily after 4 weeks · injection · 24 weeksAs given in this study (human).
Measurements
Systolic pressure change
−9.44 mm Hg
exenatide
Systolic pressure change
−1.97 mm Hg
placebo
Source sentences
Summary
Exenatide + lifestyle modification program showed greater change in weight (-6.16 +/- 0.54 kg vs -3.97 +/- 0.52 kg, P = .003), hemoglobin A(1c) (-1.21 +/- 0.09% vs -0.73 +/- 0.09%, P <.0001), systolic (-9.44 +/- 1.40 vs -1.97 +/- 1.40 mm Hg, P <.001) and diastolic blood pressure (-2.22 +/- 1.00 vs 0…
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
Report a problemFND-2039932605
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced diastolic blood pressure more than placebo with the same lifestyle program.
In plain wordsIn patients with diabetes, exenatide reduced diastolic blood pressure more than placebo with the same lifestyle program.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDiastolic blood pressure change
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Blood pressure · Cardiovascular
Studied dose
5 microg twice daily, increased to 10 microg twice daily after 4 weeks · injection · 24 weeksAs given in this study (human).
Measurements
Diastolic pressure change
−2.22 mm Hg
exenatide
Diastolic pressure change
0.47 mm Hg
placebo
Source sentences
Summary
Exenatide + lifestyle modification program showed greater change in weight (-6.16 +/- 0.54 kg vs -3.97 +/- 0.52 kg, P = .003), hemoglobin A(1c) (-1.21 +/- 0.09% vs -0.73 +/- 0.09%, P <.0001), systolic (-9.44 +/- 1.40 vs -1.97 +/- 1.40 mm Hg, P <.001) and diastolic blood pressure (-2.22 +/- 1.00 vs 0…
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
Report a problemFND-2039932606
05HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, nausea was more frequent with exenatide than placebo during lifestyle modification.
In plain wordsIn patients with diabetes, nausea was more frequent with exenatide than placebo during lifestyle modification.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNausea
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 microg twice daily, increased to 10 microg twice daily after 4 weeks · injection · 24 weeksAs given in this study (human).
Measurements
Nausea
44.8%
exenatide
Nausea
19.4%
placebo
Source sentences
Summary
Nausea was reported more for exenatide + lifestyle modification program than placebo + lifestyle modification program (44.8% vs 19.4%, respectively, P <.001), with no difference in withdrawal rates due to adverse events (4.2% vs 5.1%, respectively, P = 1.0) or rates of hypoglycemia.
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
Report a problemFND-2039932607
06HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, withdrawal due to adverse events did not differ between exenatide and placebo.
In plain wordsIn patients with diabetes, withdrawal due to side effects did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWithdrawal due to adverse events
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Adverse events · Whole body
Studied dose
5 microg twice daily, increased to 10 microg twice daily after 4 weeks · injection · 24 weeksAs given in this study (human).
Measurements
Withdrawal
4.2%
exenatide
Withdrawal
5.1%
placebo
Source sentences
Summary
Nausea was reported more for exenatide + lifestyle modification program than placebo + lifestyle modification program (44.8% vs 19.4%, respectively, P <.001), with no difference in withdrawal rates due to adverse events (4.2% vs 5.1%, respectively, P = 1.0) or rates of hypoglycemia.
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
Report a problemFND-2039932608
07HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, hypoglycemia rates did not differ between exenatide and placebo during lifestyle modification.
In plain wordsIn patients with diabetes, low blood sugar rates did not differ between exenatide and placebo during lifestyle modification.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHypoglycemia
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Adverse events · Metabolic and weight
Studied dose
5 microg twice daily, increased to 10 microg twice daily after 4 weeks · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Nausea was reported more for exenatide + lifestyle modification program than placebo + lifestyle modification program (44.8% vs 19.4%, respectively, P <.001), with no difference in withdrawal rates due to adverse events (4.2% vs 5.1%, respectively, P = 1.0) or rates of hypoglycemia.
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
Report a problemFND-2039932609

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, caloric intake decreased similarly with exenatide and placebo during lifestyle modification.
In plain wordsIn patients with diabetes, calorie intake decreased similarly with exenatide and placebo during lifestyle modification.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCaloric intake
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Caloric intake change
−378 kcal/day
exenatide + lifestyle modification program
Caloric intake change
−295 kcal/day
placebo + lifestyle modification program
Source sentences
Summary
At 24 weeks (least squares mean +/- standard error), treatments showed similar decreases in caloric intake (-378 +/- 58 vs -295 +/- 58 kcal/day, exenatide + lifestyle modification program vs placebo + lifestyle modification program, P = .27) and increases in exercise-derived energy expenditure.
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2039932601
09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exercise-derived energy expenditure increased similarly with exenatide and placebo during lifestyle modification.
In plain wordsIn patients with diabetes, energy use from exercise increased similarly with exenatide and placebo during lifestyle modification.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeExercise-derived energy expenditure
Study
n = 194
Comparator
Placebo with the same lifestyle program
Outcome group
Exercise and physical function · Metabolic and weight
Source sentences
Summary
At 24 weeks (least squares mean +/- standard error), treatments showed similar decreases in caloric intake (-378 +/- 58 vs -295 +/- 58 kcal/day, exenatide + lifestyle modification program vs placebo + lifestyle modification program, P = .27) and increases in exercise-derived energy expenditure.
3 context sentences(design, population, supporting numbers)
Summary · context
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Summary · context
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
Summary · context
Participants were randomized to 5 microg exenatide twice daily injection + lifestyle modification program (n = 96) or placebo + lifestyle modification program (n = 98), and after 4 weeks increased their exenatide dose to 10 microg twice daily or volume equivalent of placebo.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2039932602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.